Article

Slow, Costly Process Stymies Generic Biotech Drugs

One of the pledges of the Obama administration's healthcare overhaul was to enable cheaper copies of expensive biotech drugs, but the savings may not be as deep or come as quickly as hoped.

Healthcare companies and industry experts say questions over how the market will work and the specter of patent litigation mean robust competition for generic biotech drugs might wait until the end of the decade. The regulatory requirements - which could force drugmakers to spend more money on testing - could mean eventual cost savings for payers of as little as 10 or 20 percent per treatment.

Read the full story:

http://hcp.lv/zX9DTK

Source: Reuters

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
Mehmet Oz, MD, MBA
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Nicole Bajic, MD
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo